News | Vascular Closure Devices | October 18, 2016

St. Jude Medical, Abbott to Sell Portion of Vascular Closure, EP Businesses to Terumo

The agreement is a step toward completion of Abbott's acquisition of St. Jude Medical, expected to close by year-end

 

angioseal, angio-seal, terumo, St. Jude, vascular closure devices

October 18, 2016 — Abbott and St. Jude Medical Inc. announced today an agreement to sell certain products from their electrophysiology (EP) and vascular closure portfolios to Terumo Corp. The transaction reflects a purchase price of about $1.12 billion and is subject to the successful completion of Abbott's acquisition of St. Jude Medical and antitrust regulatory approvals. 

Read the article “Abbott to Acquire St. Jude Medical,” from April 2016.

The divestiture is an all-cash transaction and will include the products globally for St. Jude Medical's Angio-Seal and Femoseal vascular closure products and Abbott's Vado Steerable Sheath. Abbott will retain its vascular closure products, which include the Perclose ProGlide Suture-Mediated Closure System, StarClose SE Vascular Closure System and Prostar XL Percutaneous Vascular Surgical System. The Angio-Seal product lines offer healthcare providers an alternative to manual compression for sealing puncture sites on patients who have undergone a catheterization procedure.

Abbott’s Vado steerable sheath is used to navigate EP ablation catheter procedures with precision to create continuous, smooth lesions. The sheath is the first design on the market that does not use pull wires for deflection, instead using connected coaxial lumens reinforced with Kevlar to provide stability in all planes. As opposed to traditional pull wire designs, this allows operators to rotate the Vado 360 degrees without torque buildup, which results in catheter whipping.

Following Abbott's acquisition of St. Jude Medical, the combined business will compete in nearly every area of the cardiovascular market and hold top positions in high-growth segments, including atrial fibrillation, structural heart and heart failure, as well as a leading position in the high-growth neuromodulation market. 

Abbott expects to mitigate any impact to its adjusted earnings per share projections related to the sale of these assets to Terumo. Abbott, St. Jude Medical and Terumo are bound by the terms of an exclusivity agreement.

For more information: www.sjm.com, www.abbott.com

Related Content

Shockwave Initiates U.S. Pivotal Study for Coronary Intravascular Lithotripsy
News | Cath Lab | January 16, 2019
Shockwave Medical Inc. has initiated its U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE...
National Academy of Engineering, Ohio University Award 2019 Russ Prize
News | Cath Lab | January 03, 2019
Ohio University and the National Academy of Engineering announced the 2019 Fritz J. and Dolores H. Russ Prize will be...
Videos | Cath Lab | January 03, 2019
This is walk through inside one of the cardiac hybrid cath labs at the...
Videos | Cath Lab | January 03, 2019
This is the newest cardiac cath lab at the ...
Study Finds Effective Treatment for Coronary Slow Flow
News | Cath Lab | December 27, 2018
Patients who arrive at the hospital with heart-attack-like symptoms have had little recourse for their chest pain if...
Shockwave Announces Collaboration With Abiomed on Physician Training
News | Cath Lab | December 14, 2018
Shockwave Medical announced a new investment and collaboration agreement with Abiomed Inc. As outlined by the agreement...
Sponsored Content | Videos | Cath Lab | October 24, 2018
Michael Flaherty, M.D., discusses a study published in Circulation Research which finds that use of hemodynamic suppo
Philips Showcases Integrated Solutions for Cardiovascular Care at TCT 2018
News | Cath Lab | September 20, 2018
At the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting, Sept. 21–25 in San Diego, Philips is showcasing...
Overlay Init